The addition of nivolumab to neoadjuvant chemotherapy significantly increased pathologic complete response among certain patients with breast cancer, according to findings published in Nature Medicine ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

近日，北京中医药大学东直门医院王勇教授和广州中医药大学王伟教授团队在Medicine Plus上发表综述文章“Anthracycline-induced cardiotoxicity: emerging mechanisms and ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma ...

CNS Pharmaceuticals (CNSP) announced the primary analysis of its clinical trial evaluating Berubicin, the first anthracycline demonstrated to ...

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint.The safety pro ...

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically ...

The significant drop in CNS Pharmaceuticals’ stock price reflects investor concerns over the commercial viability of Berubicin following these trial results. The company’s next steps will likely be ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

The American Gastroenterological Association (AGA) has released an updated clinical practice guideline on the prevention of hepatitis B virus reactivation (HBVr) in at-risk persons. The document ...